The Experts below are selected from a list of 144 Experts worldwide ranked by ideXlab platform
Lyle Isaacs - One of the best experts on this subject based on the ideXlab platform.
-
acyclic cucurbit n uril molecular contaIners enhance the solubility and bioactivity of poorly soluble pharmaceuticals
Nature Chemistry, 2012Co-Authors: Gaya Hettiarachchi, Duc Nguyen, Ben Zhang, James B Wittenberg, Peter Y Zavalij, Volker Briken, Lyle IsaacsAbstract:Acyclic cucurbituril-type molecular contaIners have been found to Increase the solubility of Insoluble pharmaceutical agents In water by up to 2,750-fold. In vitro and In Vivo Toxicology studies suggest that the contaIners are well tolerated, and paclitaxel solubilized In this manner efficiently kills HeLa and SK-OV-3 cancer cells.
-
Acyclic cucurbit[n]uril molecular contaIners enhance the solubility and bioactivity of poorly soluble pharmaceuticals
Nature Chemistry, 2012Co-Authors: Da Ma, Gaya Hettiarachchi, Duc Nguyen, Ben Zhang, James B Wittenberg, Peter Y Zavalij, Volker Briken, Lyle IsaacsAbstract:The solubility characteristics of 40–70% of new drug candidates are so poor that they cannot be formulated on their own, so new methods for IncreasIng drug solubility are highly prized. Here, we describe a new class of general-purpose solubilizIng agents—acyclic cucurbituril-type contaIners—which Increase the solubility of ten Insoluble drugs by a factor of between 23 and 2,750 by formIng contaIner–drug complexes. The contaIners exhibit low In vitro toxicity In human liver, kidney and monocyte cell lInes, and outbred Swiss Webster mice tolerate high doses of the contaIner without sickness or weight loss. Paclitaxel solubilized by the acyclic cucurbituril-type contaIners kills cervical and ovarian cancer cells more efficiently than paclitaxel alone. The acyclic cucurbituril-type contaIners preferentially bInd cationic and aromatic drugs, but also solubilize neutral drugs such as paclitaxel, and represent an attractive extension of cyclodextrIn-based technology for drug solubilization and delivery. Acyclic cucurbituril-type molecular contaIners have been found to Increase the solubility of Insoluble pharmaceutical agents In water by up to 2,750-fold. In vitro and In Vivo Toxicology studies suggest that the contaIners are well tolerated, and paclitaxel solubilized In this manner efficiently kills HeLa and SK-OV-3 cancer cells.
Mohan Srinivasan - One of the best experts on this subject based on the ideXlab platform.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Cindy Wang, Kent Thudium, Michelle Minhua Han, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan SrinivasanAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and down-modulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermInes antitumor immunity and supports the rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed usIng nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab whose antitumor activity and safety profile have been demonstrated In human clInical trials In various solid tumors.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Changyu Wang, Kent Thudium, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan Srinivasan, Sujata SinghAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and downmodulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermIne antitumor immunity and support its rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor-blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse immune-related events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab, for which antitumor activity and safety have been demonstrated In human clInical trials In various solid tumors.
Sujata Singh - One of the best experts on this subject based on the ideXlab platform.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Changyu Wang, Kent Thudium, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan Srinivasan, Sujata SinghAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and downmodulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermIne antitumor immunity and support its rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor-blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse immune-related events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab, for which antitumor activity and safety have been demonstrated In human clInical trials In various solid tumors.
Xitao Wang - One of the best experts on this subject based on the ideXlab platform.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Cindy Wang, Kent Thudium, Michelle Minhua Han, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan SrinivasanAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and down-modulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermInes antitumor immunity and supports the rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed usIng nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab whose antitumor activity and safety profile have been demonstrated In human clInical trials In various solid tumors.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Changyu Wang, Kent Thudium, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan Srinivasan, Sujata SinghAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and downmodulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermIne antitumor immunity and support its rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor-blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse immune-related events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab, for which antitumor activity and safety have been demonstrated In human clInical trials In various solid tumors.
Haichun Huang - One of the best experts on this subject based on the ideXlab platform.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Cindy Wang, Kent Thudium, Michelle Minhua Han, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan SrinivasanAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and down-modulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermInes antitumor immunity and supports the rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed usIng nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab whose antitumor activity and safety profile have been demonstrated In human clInical trials In various solid tumors.
-
In vitro characterization of the anti pd 1 antibody nivolumab bms 936558 and In Vivo Toxicology In non human primates
Cancer immunology research, 2014Co-Authors: Changyu Wang, Kent Thudium, Xitao Wang, Haichun Huang, D Feingersh, C Garcia, Y Wu, Michelle R Kuhne, Mohan Srinivasan, Sujata SinghAbstract:The programmed death-1 (PD-1) receptor serves as an immunologic checkpoInt, limitIng bystander tissue damage and preventIng the development of autoimmunity durIng Inflammatory responses. PD-1 is expressed by activated T cells and downmodulates T-cell effector functions upon bIndIng to its ligands, PD-L1 and PD-L2, on antigen-presentIng cells. In patients with cancer, the expression of PD-1 on tumor-InfiltratIng lymphocytes and its Interaction with the ligands on tumor and immune cells In the tumor microenvironment undermIne antitumor immunity and support its rationale for PD-1 blockade In cancer immunotherapy. This report details the development and characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor-blockIng monoclonal antibody. Nivolumab bInds to PD-1 with high affInity and specificity, and effectively Inhibits the Interaction between PD-1 and its ligands. In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokIne production In the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays. No In vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of nivolumab and activated T cells as targets. Nivolumab treatment did not Induce adverse immune-related events when given to cynomolgus macaques at high concentrations, Independent of circulatIng anti-nivolumab antibodies where observed. These data provide a comprehensive preclInical characterization of nivolumab, for which antitumor activity and safety have been demonstrated In human clInical trials In various solid tumors.
